These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 12774208

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C.
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [Abstract] [Full Text] [Related]

  • 5. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ.
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [Abstract] [Full Text] [Related]

  • 6. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK, Cordato DJ, O'Rourke F.
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of levodopa-induced motor complications.
    Stocchi F, Tagliati M, Olanow CW.
    Mov Disord; 2008 May; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [Abstract] [Full Text] [Related]

  • 11. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS.
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN.
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM.
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [Abstract] [Full Text] [Related]

  • 18. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN.
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.